Acurx Pharmaceuticals, Inc. (ACXP) News

Acurx Pharmaceuticals, Inc. (ACXP): $2.55

0.24 (-8.60%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

Add ACXP to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#251 of 360

in industry

Filter ACXP News Items

ACXP News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ACXP News Highlights

  • ACXP's 30 day story count now stands at 3.
  • Over the past 4 days, the trend for ACXP's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about ACXP are AWH, RELI and AIRS.

Latest ACXP News From Around the Web

Below are the latest news stories about ACURX PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ACXP as an investment opportunity.

Acurx Announces Positive Phase 2b Results Showing 100% of Patients Who Had Clinical Cure with Ibezapolstat Also Had Sustained Clinical Cure

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced positive Phase 2b results showing 100% of CDI patients who had CC with ibezapolstat, the company's late-stage antibiotic candidate, also had SCC.

Yahoo | December 11, 2023

New to The Street TV Features Five Corporate Guest Interviews, Episode 537 Airs on the FOX Business Network, Monday, December 11, 2023, at 10:30 PM PT

New to The Street TV Features Five Corporate Guest Interviews, Episode 537 Airs on the FOX Business Network, Monday, December 11, 2023, at 10;30 PM PT Episode 537: 1). Reliance Global Group, Inc. (NASDAQ: RELI) (NASDAQ: RELIW) ($RELI) 2). Aspira Women's Health (NASDAQ: AWH) ($AWH) 3). Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ($ACXP) 4).The Business of Blockchain, 5).Sekur Private Data, Ltd. (OTCQB: SWISF) (CSE: SKUR) (FRA: GDT0) (Sekur®) - https://www.newtothestreet.com/ NEW YORK, Dec. 08, 202

Yahoo | December 8, 2023

New to The Street TV Announces Its Episode 536 Lineup, Five Corporate Guest Interviews, Broadcasted as Sponsored Program on Bloomberg TV, Tonight, Thursday, December 7, 2023, at 9:30 PM PT

New to The Street TV Announces Its Episode 536 Lineup, Five Corporate Guest Interviews, Broadcasted as Sponsored Program on Bloomberg TV, Tonight, Thursday, December 7, 2023, at 9:30 PM PT Episode 536: 1). - Reliance Global Group, Inc. (NASDAQ: RELI) (NASDAQ: RELIW) ($RELI) 2). Aspira Women's Health (NASDAQ: AWH) ($AWH) 3). Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ($ACXP) 4). The Business of Blockchain 5).Sekur Private Data, Ltd. (OTCQX: SWISF) (CSE: SKUR) (FRA: GDT0) (Sekur®) - https://www.ne

Yahoo | December 7, 2023

New to The Street Announces Five Corporate Interviews, Episode 535, Airing on the FOX Business Network on Monday, December 4, 2023, at 10:30 PM PT

New to The Street Announces Five Corporate Interviews, Episode 535, Airing on the FOX Business Network on Monday, December 4, 2023, at 10:30 PM PT Episode 535: 1).Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ($ACXP) 2). Reliance Global Group, Inc. (NASDAQ: RELI) (NASDAQ: RELIW) ($RELI) 3).American Conservative Values ETF (NYSE: ACVF) ($ACVF) 4).PetVivo Holdings, Inc. (NASDAQ: PETV) (NASDAQ: PETVW) ($PETV) 5). Sekur Private Data, Ltd. (OTCQX: SWISF) (CSE: SKUR) (FRA: GDT0) (Sekur®) - https://www.ne

Yahoo | December 1, 2023

New to The Street Announces its Five Business Guest Interviews, Episode 533, Airs on the FOX Business Network on Monday, November 27, 2023, at 10:30 PM PT

New to The Street Announces its Five Business Guest Interviews, Episode 533, which airs on the FOX Business Network on Monday, November 27, 2023, at 10:30 PM PT Episode 533 will air the following five (5) business interviews: 1). Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ($ACXP) 2). Coastal Kapital, LLC. 3). American Conservative Values ETF (NYSE: ACVF) ($ACVF) 4). PetVivo Holdings, Inc. (NASDAQ: PETV) (NASDAQ: PETVW) ($PETV) 5). Sekur Private Data, Ltd. (OTCQX: SWISF) (CSE: SKUR) (FRA: GDT0) (

Yahoo | November 24, 2023

New to The Street Announces Episode 530 with Six Corporate Interviews, Airing on the Fox Business Network, Monday, November 20, 2023, at 10:30 PM PT

The Show Features a New Segment, “The Business of Blockchain,” with Host Jane King New to The Street Announces Episode 530 with Six Corporate Interviews, Airing on the Fox Business Network, Monday, November 20, 2023, at 10:30 PM PT Episode 530 Features: 1). Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ($ACXP) 2). Clean Vision Corp. (OTCQB: CLNV) ($CLNV) 3). AppTech Payments Corp. (NASDAQ: APCX) (NASDAQ: APCXW) ($APCX) ("AppTech") 4). ProStar Holdings, Inc. (OTCQX: MAPPF) (TSXV: MAPS) (FSE: 5D00) (

Yahoo | November 17, 2023

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q3 2023 Earnings Call Transcript

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q3 2023 Earnings Call Transcript November 14, 2023 Acurx Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.23952, expectations were $-0.28. Operator: Ladies and gentlemen, good morning, and welcome to the Acurx Pharmaceuticals Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. A brief […]

Yahoo | November 15, 2023

Acurx Pharmaceuticals, Inc. Reports Third Quarter 2023 Results and Provides Business Update

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the third quarter ended September 30, 2023.

Yahoo | November 14, 2023

12 Best Day Trading Stocks To Buy

In this article, we discuss the 12 best day trading stocks to buy. If you want to read about some more day trading stocks, go directly to 5 Best Day Trading Stocks To Buy. Over the past few years, the rise of a new generation of stock traders that like to engage in risky bets, […]

Yahoo | November 9, 2023

Acurx Announces Positive Top-Line Ibezapolstat Phase 2 Efficacy Results with 96% Clinical Cure Rate in Patients with C. difficile Infection

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced efficacy results from the Phase 2 clinical trial (Phase 2a segment and Phase 2b segment) of ibezapolstat for the treatment of C. difficile Infection (CDI).

Yahoo | November 2, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!